SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving massive market activity following its high-profile Nasdaq debut, with community members fiercely debating its trillion-dollar valuation against the company's ongoing lack of profitability. While some retail investors are treating the hype as a multi-generational growth play, others are expressing significant caution, framing the current trading environment as a high-stakes liquidity event prone to extreme volatility.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing significant market volatility as investors weigh its upcoming Nasdaq-100 inclusion against a liquidity rotation into the high-profile SpaceX IPO. While the community remains divided between those capitalizing on the Nasdaq-driven buying pressure and others bracing for a post-IPO cooling of the broader space sector, long-term investors are highlighting Rocket Lab's established launch cadence and backlog as key differentiators from its peers.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant volatility as investors weigh the resolution of its fee dispute with Publicis against broader concerns regarding the company's executive leadership and intense short-selling pressure. The community is heavily divided, with some traders viewing the current price as a generational buying opportunity, while others remain skeptical and frustrated by the stock's inability to sustain upward momentum.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is currently trending due to a wave of positive analyst sentiment and price target upgrades following a strong earnings report that highlighted a shift to profitability and record platform engagement. Investors are actively debating the company's long-term growth as a streaming gatekeeper while monitoring technical levels for a potential breakout toward previous highs.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is experiencing significant volatility and downward pressure as investors re-evaluate its scarcity premium ahead of the highly anticipated SpaceX IPO. The community is actively debating whether the stock is a long-term value play based on its holdings in SpaceX, Anthropic, and OpenAI or a 'sell-the-news' trap worsened by recent share dilution.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently in focus as investors analyze the stock's significant indirect exposure to the upcoming SpaceX IPO, viewing it as a potential value proxy for the space sector. Community sentiment is deeply divided between long-term holders betting on the revaluation of EchoStar's satellite assets and SpaceX stake, and short-sellers who are expressing concerns over the company's debt load and capital structure.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors react to positive Phase 1 clinical data for subcutaneous Briumvi in myasthenia gravis and the initiation of a registration-directed Phase 2 trial. The community remains focused on potential M&A activity, with discussions weighing the stock's long-term growth potential against continued volatility from high short interest.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant volatility as market liquidity rotates into the high-profile SpaceX IPO, causing a sector-wide pullback despite upcoming satellite launch catalysts. While some investors are concerned about potential sector drag and aggressive institutional selling, others view the sharp decline as a strategic buying opportunity for a long-term play on direct-to-device broadband technology.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is experiencing significant volatility and high volume as investors weigh the stock's role in the broader space sector against the massive market debut of SpaceX. The community is actively debating whether the recent price action represents a buying opportunity in a fundamental growth play or a short-term trap amid shifting capital and ongoing dilution concerns.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

XOVR is trending as investors debate its role as a proxy for SpaceX exposure, with community members actively comparing its private-public crossover structure to other vehicles like DXYZ and NASA. Sentiment remains polarized, as some shareholders express frustration over stagnant price action, while others highlight the long-term value proposition of gaining liquidity and venture-style access to private industry leaders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +64.91% and +9.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HC Wainwright Issues Pessimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Monday, May 4th. HC Wainwright analyst M. Caufield now forecasts that t...

Tarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Monday...

D.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

D.A. Davidson & CO. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange...

Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +8.87% and +1.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Jennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Jennison Associates LLC cut its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange...

Tarsus Pharmaceuticals is Now Oversold (TARS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Universal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,857 shares of the...

Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent 13F filing with the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on Tarsus Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $98.00 price target for the company...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Current Price	$61.90
Prev Close	$62.61
Open	$63.51
Dividend Yield	0.00%
50-Day Moving Average	$64.05
Beta	0.75
Avg. Volume	789,234.74
PE Ratio	-55.24

52-Week High	$85.25
52-Week Low	$38.51
Market Capitalization	$2.69B
EPS (Annual)	-$1.59
Price to Book	7.72
Revenue Per Employee	$1.22M

TARSTarsus Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TARS News